Central Application of Aliskiren, a Renin Inhibitor, Improves Outcome After Experimental Stroke Independent of Its Blood Pressure Lowering Effect by پناهپور, حمداله et al.
ORIGINAL RESEARCH
published: 04 September 2019
doi: 10.3389/fneur.2019.00942
Frontiers in Neurology | www.frontiersin.org 1 September 2019 | Volume 10 | Article 942
Edited by:
Anna Rosell,
Vall d’Hebron Research Institute
(VHIR), Spain
Reviewed by:
Jesus Miguel Pradillo,
Complutense University of
Madrid, Spain
Giuseppe Faraco,
Weill Cornell Medicine, United States
*Correspondence:
Nikolaus Plesnila
nikolaus.plesnila@
med.uni-muenchen.de
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Stroke,
a section of the journal
Frontiers in Neurology
Received: 10 February 2019
Accepted: 14 August 2019
Published: 04 September 2019
Citation:
Panahpour H, Terpolilli NA,
Schaffert D, Culmsee C and Plesnila N
(2019) Central Application of Aliskiren,
a Renin Inhibitor, Improves Outcome
After Experimental Stroke Independent
of Its Blood Pressure Lowering Effect.
Front. Neurol. 10:942.
doi: 10.3389/fneur.2019.00942
Central Application of Aliskiren, a
Renin Inhibitor, Improves Outcome
After Experimental Stroke
Independent of Its Blood Pressure
Lowering Effect
Hamdollah Panahpour 1,2†, Nicole A. Terpolilli 1,3,4†, David Schaffert 5, Carsten Culmsee 6 and
Nikolaus Plesnila 1,4*
1 Laboratory of Experimental Stroke Research, Institute for Stroke and Dementia Research (ISD), Munich University Hospital,
Munich, Germany, 2Department of Physiology, Medical School, Ardabil University of Medical Sciences, Ardabil, Iran,
3Department of Neurosurgery, Munich University Hospital, Munich, Germany, 4Munich Cluster for Systems Neurology
(SyNergy), Munich, Germany, 5 Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians University,
Munich, Germany, 6 Institute for Pharmacology and Clinical Pharmacy, University of Marburg, Marburg, Germany
Epidemiological studies suggest that pharmacological reduction of systemic
hypertension lowers incidence and severity of stroke. However, whether the reduction of
blood pressure per se or the compounds used to reduce hypertension are responsible
for this effect received little attention. In the current study we therefore aimed to
investigate whether Aliskiren, a renin-inhibitor used to treat arterial hypertension, may
improve outcome in a mouse model of ischemic stroke when applied centrally and in
a dose not affecting blood pressure. Male C57BL/6 mice received 0.6, 2.0, or 6.0 µg
Aliskiren or vehicle by intracerebroventricular injection as a pre-treatment and were then
subjected to 60min of middle cerebral artery occlusion (MCAo). Infarct volume, brain
edema formation, mortality, antioxidant effects, and functional outcome were assessed
up to seven days after MCAo. Central administration of Aliskiren (0.6 or 2.0 µg) had
no effect on systemic blood pressure but significantly reduced infarct volume and brain
edema formation, blunted mortality, and improved neurological outcome up to 1 week
after MCAo. Due to the central and prophylactic administration of the compound, we
cannot make any conclusions about the potency of Aliskiren for acute stroke treatment,
however, our study clearly demonstrates, that in addition to lowering blood pressure
Aliskiren seems to have a direct neuroprotective effect. Hence, renin-inhibitors may be
an effective addition to prophylactic treatment regimens in stroke patients.
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INTRODUCTION
Epidemiological studies suggest that treating arterial hypertension reduces the incidence and the
severity of ischemic and hemorrhagic stroke (1, 2). This effect is attributed to the reduction of
hypertension, however, an alternative explanation could be that pharmacological compounds used
to reduce systemic blood pressure may in addition also have neuroprotective effects.
Panahpour et al. Renin Inhibition in Experimental Ischemic Stroke
One pathway that has been implicated in the pathophysiology
of hypertension and ischemic stroke, is the renin-angiotensin-
system (RAS) (3). The RAS plays a crucial role in themaintenance
of blood pressure and blood volume. Drops in blood pressure
or blood volume lead to secretion of renin, a protease, which
hydrolyses angiotensinogen to angiotensin I (Ang I). Ang I is
converted to Angiotensin II (Ang II), a strong vasoconstrictor,
by angiotensin converting enzyme (ACE). Ang II activates
Angiotensin 1 receptors (AT1R), which induce vasoconstriction,
inflammatory changes and oxidative stress, and Angiotensin 2
receptors (AT2R) whichmediate vasodilation via Angiotensin 1-7
(Ang1-7) and MAS receptors, the so called “alternative axis” (4).
Accordingly, the RAS reduces blood pressure via inhibition
of AT1 receptors and/or activation of AT2 receptors, but may
well deteriorate ischemic damage thorough vasoconstriction and
the other actions of AT1 receptors (4). In fact, inhibition of
ACE or angiotensin type 1 receptors were shown to reduce
arterial hypertension and to effectively prevent cerebro-vascular
events (5, 6), while also being protective after cerebral ischemia.
Further, activation of the AT2 axis inferred neuroprotection after
experimental stroke (7–9).
Despite this elegant work on the downstream members of
the RAS, relatively little is known about the role of renin after
stroke, the first step of the RAS-cascade, which is the rate-limiting
enzyme of the whole system (10–12). The activity of renin can be
inhibited by the small molecule Aliskiren, a clinically frequently
used compound, which was shown to effectively reduce arterial
hypertension (13–16), and its sequels, that is nephropathy (17,
18) and myocardial infarction (19, 20). With regard to cerebral
ischemia, however, it is not known whether Aliskiren prevents
stroke only by its blood pressure lowering effect or possibly also
by a direct neuroprotective effect on the brain. To investigate
this hypothesis we applied not blood pressure lowering doses of
Aliskiren by intracerebroventricular injection to mice, subjected
them to experimental stroke, and investigated infarct volume,
brain edema formation, and neurological function for up to seven
days thereafter.
MATERIALS AND METHODS
All protocols used were in accordance with international
guidelines, the Basel Declaration, and approved by the
Government of Upper Bavaria (protocol number 55.2-1-
54-2531-118-05). Results are reported according to the ARRIVE
guidelines (21). Mice were randomly assigned to experimental
groups by drawing lots. Surgical preparation, physiological
monitoring, and data analysis were performed by an investigator
(H.P.) blinded to the treatment of the animals.
TRANSIENT CEREBRAL ISCHEMIA
Cerebral ischemia was induced by middle cerebral artery
occlusion (MCAo) as previously described (22, 23). Briefly,
after induction of isoflurane anesthesia (induction: 30 s at 4%,
continuation with 1.0–1.2% in 30% O2 and 70% N2O), a silicone
covered 8-0 monofilament (Ethilon R©, Ethicon, Germany) was
advanced intravascularly via the left common carotid artery and
the left internal carotid artery (ICA) until it occluded the middle
cerebral artery at the MCA bifurcation. Cerebral blood flow was
continuously and non-invasively measured over the left MCA
territory via Laser Doppler flowmetry (LDF, Perimed, Sweden)
during the procedure. MCAo was confirmed by a drop of CBF
to <20% of baseline. The filament was then fixed and animals
were allowed to wake up from anesthesia. Later on animals were
re-anesthetized and the filament was removed 60min after the
initiation of ischemia. Animals were kept in an incubator heated
to 32◦C for 6 h after surgery to avoid hypothermia.
QUANTIFICATION OF INFARCT VOLUME
Twenty four hours or seven days after reperfusion mice
were sacrificed in deep isoflurane anesthesia and brains
were removed and frozen on powdered dry ice. Twelve
sequential 10µm coronal Nissl sections were prepared every
500µm. Infarct volume was calculated as previously described
by histomorphometry using a digital image analysis system
(Olympus DP–Soft, Munich, Germany) (23–25). Infarct volumes
were corrected for brain swelling and were calculated for the
whole brain as well as for subcortical and cortical brain regions.
MEASUREMENT OF BRAIN EDEMA
Brain water content was assessed as previously described
(26): after brain removal 24 h after reperfusion olfactory bulb,
cerebellum, and medulla oblongata were dissected, cerebral
hemispheres divided and weighed (wet weight, WW). After
drying the tissue at 110◦C for 24 h the dry weight (DW) was
obtained. Brain water content was calculated using the following
formula: (WW–DW)/WW× 100.
EVALUATION OF NEUROLOGICAL
DEFICITS
All neurological testing was performed by a researcher blinded
to treatment type and group. Neurological deficits were assessed
immediately before and 24 h afterMCAo using amodified 6 point
scale (Neurological deficit score, NDS) assessing spontaneous
motor function and tail suspension; in the chronic group
the testing was repeated every 24 h. Scoring was performed
as described: 1 = Normal motor function (spontaneous, tail
suspension), 2 = Normal spontaneous motor function, flexion
of contralateral forelimb during tail suspension, 3 = Circling
during tail suspension, 4 = Spontaneous circling, 5 = Leaning
to contralateral side, loss of righting reflex, 6 = No spontaneous
motor activity.
DRUG ADMINISTRATION
The specific renin inhibitor Aliskiren was extracted from
a commercially available formulation (Novartis, Basel,
Switzerland), purified to >99%, and administered at a
concentration of 0.6, 2.0, or 6.0 µg in 2 µl saline 45min
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FIGURE 1 | Experimental setup. (A) Dose finding study. (B) Assessment of infarct volume and (C) brain water content 24 h after MCAo. (D) Measurement of
antioxidant enzyme activity 24 h after MCAo. (E) Evaluation of outcome as assessed by Neurological Deficit Score for 7 days after MCAo.
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before induction of MCAo by intracerebroventricular (i.c.v.)
administration (0.9mm left and 0.1mm posterior to the bregma;
depth: 3.1mm). Vehicle treated animals received 2 µl of
saline (vehicle).
ASSESSMENT OF ANTIOXIDANT ENZYME
ACTIVITIES AND LIPID PEROXIDATION
Twenty four hours after induction of ischemia, animals were
sacrificed. The ischemic hemisphere was dissected, weighed
and homogenized (1:6) in phosphate buffered saline (pH 7.4)
with 0.1mM EDTA. After centrifugation at 10,000 g for 15min
at 4◦C, the resulting supernatant was used for analysis. The
concentration of malondialdehyde (MDA)was determined using
a colorimetric assay kit (# 10009055, Cayman Chemicals, USA).
The enzyme activities of superoxide dismutase (SOD, #706002),
catalase (CAT, #707002), and glutathione peroxidase (GPX,
#703102) in brain tissue homogenate were measured using
respective assay kits (Cayman Chemicals, USA).
EXPERIMENTAL GROUPS
For dose finding (see Figure 1A for schematic drawing of the
experimental setup) Aliskiren was injected i.c.v. in incrementing
doses every 20min (0.6, 1.4, and 4 µg drug in 2 µl physiological
saline) to achieve the cumulative doses of 0.6, 2, and 6 µg
in CSF; the control group received an equal volume of saline.
Mean arterial blood pressure (MAP, measured using a femoral
artery catheter), oxygen saturation, heart rate (measured by an
oxygen saturation sensor at the hind paw), and body temperature
(rectal temperature probe) were continuously measured. At the
TABLE 1 | Blood gas analysis.
Vehicle group Aliskiren
pH 7.26 ± 0.04 7.31 ± 0.03
pO2 170 ± 10 mmHg 194 ± 5 mmHg
pCO2 42 ± 8 mmHg 39 ± 4 mmHg
end of each experiment arterial blood samples were collected
for blood gas analysis. Infarct volumes and neurological deficits
were investigated 24 h after 60min MCAo in four groups (n = 7
mice each; see Figure 1B): (1) Vehicle, (2) 0.6 µg Aliskiren, (3)
2 µg Aliskiren, (4) 6 µg Aliskiren. Treatment was administered
i.c.v. 45min before induction of MCAo. Brain edema formation
and neurological outcome (Figure 1C) were assessed 24 h after
60minMCAo in the following groups (n= 7 each): (1) Sham, (2)
MCA occlusion only, (3) MCAo and Vehicle, MCAo and (4) 0.6
µg Aliskiren, (5) 2 µg Aliskiren, and (6) 6 µg Aliskiren; again,
injections were administered 45min before induction of MCAo.
As both groups were operated under the same conditions, the
results for neurological outcome are summarized (n = 7). Lipid
peroxidation was assessed 24 h after MCAo induction in animals
that received 2 µl Aliskiren or vehicle 45min before induction of
ischemia (n = 7 each, Figure 1D). Lastly, neurological function
and bodyweight were assessed before and every 24 h after 60min
ofMCAocclusion over 7 days; 45min before induction ofMCAo,
Aliskiren (2 µg) in 2 µl or 2 µl saline were injected i.c.v. (n = 8
each group, Figure 1E).
FIGURE 2 | Dose finding. Mean arterial blood pressure is not affected by
injection of increasing doses of Aliskiren; after a cumulative dose of 6 µg MAP
tends to lower, therefore no higher concentration was used.
TABLE 2 | Physiological parameters during dose finding.
Injection 1 (0.6 µg) Injection 2 (1.4 µg) Injection 3 (4 µg)
Before After Before After Before After
Heart rate (beats/min)
Vehicle group 615 ± 26 600 ± 14 596 ± 10 597 ± 8 594 ± 5 596 ± 5
Aliskiren 632 ± 7 622 ± 6 618 ± 5 613 ± 5 610 ± 6 595 ± 7
Temperature (◦C)
Vehicle group 37.3 ± 0.2 37.3 ± 0.2 37.3 ± 0.2 37.3 ± 0.2 37.3 ± 0.2 37.3 ± 0.2
Aliskiren 37.4 ± 0.1 37.3 ± 0.1 37.3 ± 0.2 37.2 ± 0.1 37.3 ± 0.1 37.3 ± 0.1
Oxygen saturation (%)
Vehicle group 98.1 ± 0.4 98.7 ± 0.3 98.0 ± 0.8 97.8 ± 0.6 98.2 ± 0.6 98.7 ± 0.4
Aliskiren 97.6 ± 1.7 98.1 ± 1.0 97.7 ± 1.1 97.7 ± 1.3 97.5 ± 1.5 97.8 ± 1.1
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FIGURE 3 | Effect of Aliskiren on post-ischemic brain damage 24 h after MCAo. (A) CBF after induction of MCAo. Cerebral blood flow drops to <20% of baseline
immediately after filament occlusion of the MCA in all groups. (B–D) Infarct volumes 24 h after MCAo. (B) Total infarct volume is significantly reduced in the 0.6 and 2
µg Aliskiren treatment groups. (C) Subcortical infarct volume was also reduced in these groups while (D) cortical infarct volumes were only significantly smaller in the 2
µg group compared to vehicle treated animals. (E) Exemplary coronal Nissl sections 24 h after MCAo.
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FIGURE 4 | Brain edema formation and neurological outcome after renin
inhibition. (A) Brain water content 24 h after MCAo. Brain water content in the
non-ischemic right hemisphere of all MCAo groups was not altered compared
to sham operated animals; all animals that underwent ischemia showed
significant brain edema formation in the left, i.e., ischemic hemisphere. Brain
water content was significantly reduced by application of 0.6 µg Aliskiren.
(B) Neurological deficit score after renin inhibition. Twenty four hours after
MCAo all animals had significant motor deficits; Aliskiren 0.6 µg significantly
improved the neurological scores; higher doses tended to reduce the score
but did not have a significant effect on the animals performance.
STATISTICAL ANALYSIS
Sample size calculations were performed using SigmaStat
(Version 13.0, Jandel Scientific, Erkrath, Germany) with the
following parameters: alpha error = 0.05, beta error = 0.2,
calculated standard deviation ranged from 15 to 20% (depending
on the parameter investigated), and a biologically relevant
difference of 30%. After performing normality and an equal
variance tests the Mann-Whitney rank sum test was used for
comparisons between two groups and Analysis of Variance
(ANOVA) on ranks was performed for multi group comparisons.
Differences between groups were considered significant at p <
0.05. All data are presented as mean± standard error of themean
(SEM), if not indicated otherwise.
RESULTS
Dose Finding
Repetitive injections of Aliskiren in increasing doses did
not affect blood gas parameters (Table 1), heart rate, body
temperature, or oxygen saturation (Table 2). Mean arterial blood
pressure was slightly lowered after injection of a cumulative dose
of 6 µg (Figure 2); higher doses (up to 20 µg, data not shown)
induced a significant decrease of blood pressure. Therefore, the
first set of experiments on neuroprotection were performed with
a maximum dose of 6 µg.
Ischemic Brain Damage 24h After MCAo
Immediately after induction of filament occlusion of the
left MCA, cerebral blood flow over the left MCA territory
dropped below 20% of baseline cerebral perfusion in all groups
(Figure 3A). Twenty four hours after 60min of transient MCA
ischemia, total infarct volume was significantly lower in the 0.6
and 2.0 µg Aliskiren groups as compared to vehicle treated
controls (Figure 3B; vehicle: 91.7 ± 7.7 mm3; 0.6 µg Aliskiren:
58.9 ± 8.7 mm3, p < 0.003; 2 µg Aliskiren: 56.0 ± 7.1 mm3,
p< 0.003; 6µg Aliskiren: 63.9± 8.5mm3, p= 0.165). Subcortical
infarct volume (Figure 3C) was significantly decreased in both
the 0.6 µg as well as the 2 µg Aliskiren group (p < 0.003 vs.
vehicle control); cortical infarct volume was only significantly
lower in the 2 µg Aliskiren group (Figure 3D, p < 0.008).
Figure 3E shows exemplary coronal brain sections for all groups.
Brain water content in the right (non-ischemic) hemisphere
(Figure 4A, left side) was not altered in the treatment or vehicle
groups as compared to sham operated animals (sham) or animals
that underwent MCA occlusion without i.c.v. injection (MCA
only). MCA occlusion led to a significant increase of brain water
content in the left hemisphere in all MCAo groups compared
to sham operated animals indicating the formation of brain
edema under these conditions (Figure 4A right side, p < 0.05
vs. sham). Brain edema formation was significantly reduced after
0.6 µg Aliskiren (p < 0.007 vs. vehicle); higher doses had no
significant effect.
Effect of Renin Inhibition on Post-Ischemic
Neurologic Deficits
MCAo lead to significant deterioration of motor function as
assessed by the neurological deficit score; mice in the 0.6 µg
Aliskiren group achieved significantly better scores than vehicle
treated animals (Figure 4B). Higher doses did not improve
neurological outcome.
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FIGURE 5 | Effects of Aliskiren (2 µg) on lipid peroxidation and brain tissue antioxidant enzyme activities in brain tissue homogenate of studied groups 24 h after
MCAO. MDA, malondialdehyde; SOD, superoxide dismutase; CAT, catalase; GPX, glutathione peroxidase (n = 7). Values are mean ± SEM.
†
p < 0.001, +p < 0.01,
and #p < 0.05 compared with sham group; **p < 0.01 and *p < 0.05 compared with vehicle group.
Assessment of Lipid Peroxidation Enzyme
Activity
Ischemia and reperfusion resulted in a significantly
increased MDA concentration and reduced antioxidant
enzyme activities in the ischemic hemispheres as compared
to the sham group, consistent with enhanced lipid
peroxidation after ischemic stroke. Treatment with Aliskiren
significantly reduced the MDA concentration (p < 0.01) and
elevated superoxide dismutase and glutathione peroxidase
activities (p < 0.05 and p < 0.01 vs. vehicle group,
respectively, Figure 5).
Effects of Renin Inhibition on Outcome
Parameters Over 7 Days After MCAo
Based on the observation that Aliskiren improved
histopathological and functional outcome 24 h after experimental
stroke, we wanted to evaluate if this effect lasted long-term, i.e.,
for at least 1 week. Since only 2 µg of Aliskiren reduced
subcortical and cortical infarct volumes we decided to use this
doe for these experiments.
Seven days after 60min MCAo vehicle treated mice showed
a mortality of 50% (Figure 6A). Interestingly, all mice receiving
Aliskiren survived. The long-term protective effect of Aliskiren
is also impressively exemplified by a less pronounced weight
loss in the treatment group 3, 4, and 5 days after MCAo
(Figure 6B) and by a significantly better functional outcome
staring from day 2 after MCAo until the end of the observation
period (Figure 6C).
DISCUSSION
Here, we report that central application of the renin antagonist
Aliskiren, a clinically used antihypertensive drug, protects the
brain after experimental ischemic stroke independent of its blood
pressure lowering activity. Aliskiren significantly attenuated
brain edema formation and stroke volume, blunted mortality
and improved neurological outcome in a murine stroke model.
Hence, the clinically observed effect of Aliskiren on stroke
outcome may not only be related to its effect on blood pressure,
but also to a direct effect of renin on the pathophysiology of
ischemia-induced brain damage.
In order to test the hypothesis of the current study, namely
whether the antihypertensive drug Aliskiren may have effects
on the ischemic brain beyond its actions on systemic blood
pressure, we used the format of a pharmacological study. As a
prerequisite for such a study type we testedmultiple dosages, took
care that the investigated compound reached the target organ
(by applying Aliskiren by intracerebroventricular injection),
carefully and extensively monitored animal physiology, and
performed and analyzed all experiments in a strictly randomized
and blinded fashion in order to avoid any investigator-induced
bias. To test the short- and long-term effect of Aliskiren in
an animal model of stroke we occluded the middle cerebral
artery for 60min using an intraluminal filament, a very well-
established and standardized model in our laboratory (24, 26,
27). This was further proven by the fact that in the current
study blood flow was reduced to ischemic levels (<20% of
baseline) in all investigated animals. The rationale of using
a transient ischemia model was that we wanted to be able
to investigate the effect of Aliskiren on neurological function
over 1 week. In order to induce neurological deficits, a
model inducing large infarcts is necessary, which, however,
is only survived by mice when the occlusion is transient.
Therefore, we could not use a permanent ischemia model,
which may have an improved translational profile, for the
current study.
Aliskiren has been used in models of cerebral ischemia before,
however, it has only been applied systemically (28, 29) and/
or in animals with arterial hypertension (29, 30). Intravenous
application of Aliskiren for 5 days beforeMCA occlusion resulted
in improved outcome and decreased mortality in severely
hypertensive rats (29) and reduced infarct volume in mice (28).
These experiments, however, did not clarify whether the observed
neuroprotection was due to a peripheral, i.e., blood pressure
lowering, or central effects of Aliskiren. This is particularly true
since it is not clear whether Aliskiren crosses the blood-brain
barrier and it is well-known that it has a low resorption rate (5%)
(31), low bioavailablity (32) and high plasma protein binding
(32) after systemic application. Therefore, little is known about
the specific central effect of Aliskiren for the development of
ischemic brain damage and the current study is the first one to
address this issue.
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FIGURE 6 | Functional outcome up to 7 days after MCAo. (A) While mortality
in the vehicle group was 50% over time all Aliskiren animals survived.
(B) Treatment animals recovered significantly quicker from post-ischemic
weight loss. (C) Starting 2 days after MCAo, Aliskiren treated mice achieved
significantly better scores for motor function.
Using the current approach we have proven that centrally
applied Aliskiren is neuroprotective after cerebral ischemia
independent of its blood pressure lowering effect. Although we
did not measure cerebral renin activity, the specificity and the
well-known and proven action of Aliskiren as a renin inhibitor
(33) allows us to assume with a high level of confidence that the
observed neuroprotective effects of Aliskiren were indeed caused
by the inhibition of renin. Taking this as given, the next important
question is directed toward the mechanisms undelaying the
observed functional and histopathological protection of Aliskiren
after cerebral ischemia.
Renin is the first and rate limiting component of the RAS. The
classical function of the RAS is the regulation of blood pressure
and salt/water homeostasis, however, it has also been implicated
in pathogenesis and outcome of ischemic injury in various organs
such as heart (34, 35) and kidney (36, 37). All components of the
RAS are present in the brain and the RAS has also been closely
studied in the context of cerebrovascular disease (38) and stroke
(4, 39, 40). Specifically, blocking angiotensin-converting enzyme
(ACE) (39–43) or AT-1 receptors (41) has been demonstrated
to be neuroprotective following ischemic stroke in experimental
animals and humans. In recent years, AT-2 (8, 44, 45) or MAS
(7) receptor activation have been proposed as another RAS-based
therapeutic approach for reducing post-ischemic brain damage
after stroke. Therefore, the most straightforward mechanistic
explanation of the current results is that the inhibition of
renin inhibits the more downstream members of the RAS
thereby replicating their well-known neuroprotective effects.
This may be a valid, but may not fully explain the quite
pronounced neuroprotective effects of Aliskiren. The reason is
that inhibition of renin may indeed inhibit the formation of
Angiotensin-1 (Ang-1), the subsequent production of Ang-2 by
ACE, and activation of damaging AT-1 signaling, however, it
would also inhibit neuroprotective AT-2 and MAS signaling.
Therefore, reduction of Ang-1 production may not fully explain
the neuroprotection currently observed with Aliskiren and
suggests that renin may have additional functions. In previous
studies using Aliskiren, the protective effects of renin inhibition
were hypothesized to be caused by a reduction of apoptotic
mechanisms as well as anti-inflammatory effects, however, the
link between renin activity and apoptotic signaling remains
quite speculative (28, 29). In the present study, we found
evidence for a reduction of ischemia-induced lipid peroxidation
and less activity impairment of antioxidant enzymes superoxide
dismutase and glutathione peroxidase. This is in keeping with
previous data obtained by Aliskiren in other organs and models
(46–48). As oxidative damage and lipid peroxidation play an
important role in the development of postischemic damage
(49–51) this finding may partially explain the neuroprotective
effect observed. Another mechanism which may have a direct
connection to the pathophysiology of cerebral ischemia is the link
between renin and the activity of endothelial nitric oxide synthase
(eNOS). This link was established since Aliskiren has been
described to increase eNOS activity (52) and phosphorylation
(53) and its protective effects were eNOS dependent (19) after
Frontiers in Neurology | www.frontiersin.org 8 September 2019 | Volume 10 | Article 942
Panahpour et al. Renin Inhibition in Experimental Ischemic Stroke
myocardial ischemia. It is therefore quite possible that the
protection observed in the current study is, at least partially,
due to restoration of eNOS activity, specifically since the activity
of eNOS is significantly reduced after ischemic stroke (54, 55)
and increasing the formation of NO has been shown to be
neuroprotective after ischemic stroke (26, 54, 56–58). These
actions of renin after stroke are quite speculative and will
therefore need further experimental validation. Another point
that has to be elucidated in further studies is whether the
Aliskiren effect observed is different at different doses.
In summary, central application of Aliskiren, a clinically
approved renin inhibitor, is neuroprotective and improves
functional outcome in a model of ischemic stroke independent of
its blood pressure lowering activity. The experimental approach
used in the current study (pre-treatment, intracerebroventricular
injection) was chosen in order to supply a proof of principle
with as little confounding factors as possible and does therefore
not allow any conclusion about the effect of Aliskiren for acute
stroke treatment. In order to further explore the therapeutic
potential of the proposed neuroprotective mechanism of central
renin inhibition after ischemic stroke more studies are needed
in order to explore a possible therapeutic window; also,
pharmacological modification of the drug which may allow for
a different route of administration are in planning. Nevertheless,
the observed neuroprotection was relevant and reproducible.
Therefore, central inhibition of renin may represent a promising
approach to protect the brain from ischemic injury when
used prophylactically. Hence, developing centrally active renin
inhibitors may provide a novel approach toward the prophylactic
treatment of ischemic brain injury.
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